Article ID Journal Published Year Pages File Type
5670529 Travel Medicine and Infectious Disease 2016 4 Pages PDF
Abstract

BackgroundTraveller's diarrhoea (TD) is the most common infectious problem for travellers, and we lack effective ways of preventing it, apart from antibiotic prophylaxis. This study aims to quantify the risk reduction of a hypothetic TD vaccine Norwegian travellers are willing to pay for.Methods1204 clients at Reiseklinikken responded to a questionnaire asking what level of effectiveness would be required of a hypothetical vaccine against TD costing US$65.Results18.7% of the respondents would buy the vaccine even if it was only 20% effective. Among respondents older than 50 years, the proportion was 28.8%.ConclusionsOur findings should encourage the development of vaccines and other preventive measures against travellers' diarrhoea.

Related Topics
Life Sciences Immunology and Microbiology Applied Microbiology and Biotechnology